Tatva Chintan Pharma Chem Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/s69cfe7xw4ctayyimoyyqc8i.pdf

Key Takeaways


SDA: The Volume-Price Disconnect

Chintan Shah: "Though our volume growth will be 50%, I expect the maximum revenue growth to cross only 25%. So, this is the irony."

PASC: Validation Nears Completion

Chintan Shah: "We have not even seen any patents being filed for what we have already done, so it is something really innovative that we come out with."

Capacity: The Bottleneck and the Fix


Segment Performance and FY25 Outlook

Chintan Shah: "If you look at that drop, it's almost 60-65% in raw material cost, and that translates into a lower price realization of the finished product. So you're maintaining your margins, but you're seeing a dramatic drop in per daily price realization."

Margins and Costs

Chintan Shah: "We continue to remain confident with these increasing volumes, we should hit EBITDA in the range of 22% to 24% next year."

Guidance & Commitments

CommitmentSpecificsTimeline
FY25 revenue growth35% overall revenue growthFY25
FY25 EBITDA margin22% to 24%FY25
SDA volume growthNearly 50% volume growth, but revenue growth capped at 25% maximumFY25
Electrolyte Salts growth150% to 160% revenue increaseFY25
PASC growth80% to 90% revenue increaseFY25
PTC growth8% to 10% revenue increaseFY25
SDA growth15% to 20% revenue increaseFY25
Dedicated solvent recovery plantCommercial operation begins, freeing reactor capacityWithin next two months
Bromine recovery plantUp and runningAugust or early September
Electrolyte salts demand uptickSignificant uptick from existing customer's automated production lineStarting August 2024
PASC agro commercial suppliesTwo products begin commercial suppliesLate Q2 / early Q3 FY25
Third agro PASC product validationFormal validation and commercializationApproximately November (delayed from August due to Red Sea crisis)
New automotive catalyst customerREACH registration and commercial supplies beginWithin next two months
New large SDA customer rampFull-scale opportunities; customer to become as large as all three existing major customers combinedEnd of this year for full-scale opportunities; 1.5 to 2 years for full ramp
FY26 SDA volumeAdditional 30-40% volume growth from EUR 7 implementationFY26
FY25 capex₹70 crore (postponed by a couple of quarters due to new plant soil testing delay)FY25
New plant decisionEither scale down to four floors or identify alternative siteAfter soil testing of three alternative locations

Key Metrics

MetricQ4 FY24
Revenue from operations₹98.3 cr, vs ₹124.5 cr in Q4 FY23
EBITDA₹15.6 cr, vs ₹16.3 cr in Q4 FY23
EBITDA margin15.9%, vs 13.1% in Q4 FY23
PAT₹9.6 cr, vs ₹17 cr in Q4 FY23
PAT margin9.8%, vs 13.6% in Q4 FY23
FY24 revenue from operations₹393.5 cr, 7% decline YoY
FY24 EBITDA₹68.2 cr, 13% increase YoY
FY24 EBITDA margin17.3%, vs 14.3% in FY23
FY24 PAT₹30.4 cr, vs ₹45.5 cr in FY23
FY24 employee expense13.9% of revenues, vs 9.7% in FY23
FY24 exports₹276.9 cr, 70% of revenue
Phase Transfer Catalysts Q4 revenue₹27.2 cr, 10% increase QoQ, 28% decline YoY
SDAs Q4 revenue₹40.8 cr, 26% increase QoQ, 26% decline YoY
Pharma and Agro Intermediates Q4 revenue₹28 cr, 11% increase QoQ, 6% decline YoY
Electrolyte Salts Q4 revenue₹1.4 cr, 16% growth QoQ, 48% growth YoY
SDA volume growth guidance (FY25)~50%, but revenue growth expected at 15-20% due to lower price realization
Electrolyte Salts revenue growth guidance (FY25)150-160% increase
PASC revenue growth guidance (FY25)80-90% growth
PTC revenue growth guidance (FY25)8-10% growth
Overall revenue growth guidance (FY25)~35%, expected to push reactor occupancy to 85-90% by year-end
FY25 EBITDA margin guidance22-24%, driven by operating leverage as volumes increase
Reactor capacity utilization (FY24)~68%, or ~50% excluding solvent recovery and waste treatment
SDA assembly capacity utilization (FY24)~30%, crossed 55% by late April/early May
FY25 CAPEX₹70 cr, for new multi-story plant, delayed by soil testing issues
IPO proceeds utilization100% of ₹207.28 cr utilized as on 31 March 2024
Average SDA realization$8.5 to $9 per kg
New PASC products revenue potentialAbove ₹200 cr combined, with the largest product above ₹100 cr